Fontolizumab (HuZAF™) pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and exposure/response relationship in patients (Pts) with moderate and severe Crohn's disease (CD)

被引：0
|
作者：
Ding, H
Maia, M
Keller, S
Colombel, JF
van Deventer, S
Gendre, JP
Reinisch, W
Rutgeerts, P
Tang, MT
机构：
来源：
GASTROENTEROLOGY | 2004年 / 126卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A465 / A465
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics (PK) and pharmacodynamics (PD) of natalizumab in active Crohn's disease patients
    Van Deventer, S
    Rutgeerts, P
    Rask-Madsen, J
    Shah, J
    Palmer, T
    Goldblum, R
    GASTROENTEROLOGY, 2002, 122 (04) : A434 - A434
  • [2] Population pharmacokinetics and exposure-response of filgotinib in patients with moderate to severe Crohn's disease
    Sharma, Shringi
    Xin, Yan
    Gao, Yuying
    Namour, Florence
    Mathias, Anita
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S36 - S36
  • [3] Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease
    Hommes, D
    Mikhajlova, T
    Stoinov, S
    Stimac, D
    Vucelic, B
    Lonovics, J
    Zakuciova, M
    D'Haens, G
    Van Assche, G
    Pearce, T
    GASTROENTEROLOGY, 2004, 127 (01) : 332 - 332
  • [4] Chronic dosing of fontolizumab (HuZAFtm), a humanized anti-Ifn-gamma antibody, in patients with moderate to severe Crohn's disease (CD)
    de Villiers, WJ
    Katz, S
    Salzberg, BA
    Kostova, N
    Korsev, I
    Pearce, T
    GASTROENTEROLOGY, 2005, 128 (04) : A111 - A111
  • [5] Pharmacokinetics of Laquinimod in Patients With Active Moderate to Severe Crohn's Disease
    D'Haens, Geert R.
    Sandborn, William
    Colombel, Jean-Frederic
    Mimrod, Dorit
    Spiegelstein, Ofer
    Brown, Kurt
    Feagan, Brian G.
    GASTROENTEROLOGY, 2014, 146 (05) : S368 - S368
  • [6] Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease
    D'Haens, G.
    Sandborn, W. J.
    Rutgeerts, P.
    Colombel, J. F.
    Mimrod, D.
    Spiegelstein, O.
    Brown, K.
    Feagan, B.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S226 - S226
  • [7] Pharmacokinetics of Adalimumab in Pediatric Patients With Moderate to Severe Crohn's Disease
    Eckert, Doerthe
    Mensing, Sven
    Sharma, Shringi
    Thakkar, Roopal
    Robinson, Anne
    Hyams, Jeffrey S.
    Rosh, Joel R.
    Ruemmele, Frank
    Awni, Walid M.
    GASTROENTEROLOGY, 2013, 144 (05) : S228 - S228
  • [8] Population PK/PD Modeling for Evaluation of Filgotinib Efficacy in Subjects with Moderate to Severe Crohn's Disease
    Meng, Amy
    Sharma, Shringi
    Xin, Yan
    Namour, Florence
    Mathias, Anita
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S17 - S17
  • [9] Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of moxetumomab pasudotox (Moxe), an immunotoxin targeting CD22, in adult patients (Pts) with relapsed or refractory hairy cell leukemia (HCL).
    Balic, Kemal
    Standifer, Nathan
    Santiago, Linda
    Kuruvilla, Denison
    Yao, Nai-Shun
    Kreitman, Robert J.
    Pastan, Ira
    Li, Xia
    Liang, Meina
    Vainshtein, Inna
    Tseng, Chih-Ming
    Faggioni, Raffaella
    Roskos, Lorin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Gasink, Christopher
    Jacobstein, Douglas
    Szapary, Philippe
    Johanns, Jewel
    Gao, Long-Long
    Davis, Hugh M.
    Hanauer, Stephen B.
    Feagan, Brian G.
    Ghosh, Subrata
    Sandborn, William J.
    GASTROENTEROLOGY, 2018, 154 (06) : 1660 - 1671
12345